MyJournals Home  

RSS FeedsSurgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For? (European Urology)

 
 

19 july 2019 05:00:57

 
Surgical Safety of Cytoreductive Nephrectomy Following Systemic Therapy: What Should We Look For? (European Urology)
 


In this issue of European Urology, De Bruijn et al [1] report on safety outcomes with a focus on adverse events (AEs) caused by surgery or systemic therapy in the SURTIME trial [2]. The European Organisation for Research and Treatment of Cancer 30073 SURTIME trial was an open-label, multicentre, randomised controlled study conducted at 19 centres in the Netherlands, Belgium, UK, and Canada. Eligible patients had histologically confirmed, previously untreated, metastatic renal cell carcinoma (mRCC) of the clear cell subtype with a resectable asymptomatic primary tumour in situ and required systemic therapy with sunitinib.


 
176 viewsCategory: Urology
 
Reply to Chen Cheng, Sunxiang Ma, and Yang Liu`s Letter to the Editor re: Dan Wood, Andrew Baird, Luca Carmignani, et al. Lifelong Congenital Urology: The Challenges for Patients and Surgeons. Eur Urol 2019;75:1001-7 (European Urology)
Re: Brandon A. Mahal, Mohammed Alshalalfa, Daniel E. Spratt, et al. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. Eur Urol 2019;75:1038-40 (European Urology)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten